Aquestive Therapeutics, Inc. AQST Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$8.06M+74.7% | -$31.86M-106% | -$15.45M-14.0% | -$13.55M+40.9% | -$22.93M-34.4% | ||
| $113K-13.1% | $130K-6.5% | $139K-0.7% | $140K+0.7% | $139K-5.4% | ||
| $2.32M+68.5% | $1.38M-50.5% | $2.78M+47.4% | $1.88M+18.7% | $1.59M-34.0% | ||
| $2.29M-16.8% | $2.75M0.0% | $2.75M0.0% | $2.75M-0.1% | $2.75M+1.9% | ||
| $1.9M— | —— | —— | $927K-19.7% | $1.15M+218% | ||
| -$17.97M-193% | $19.25M— | —— | —— | $1.91M-27.7% | ||
| -$2.8M-155% | $5.09M— | —— | —— | -$2.78M— | ||
| $340K— | —— | —— | -$2.68M-534% | -$423K-132% | ||
| -$6K-500% | -$1K+90.9% | -$11K-119% | $57K+224% | -$46K-39.4% | ||
| -$272K0.0% | -$272K+0.4% | -$273K— | —— | -$261K0.0% | ||
| -$10.9M-283% | $5.96M— | $0-100% | $1.35M-57.0% | $3.13M+235% | ||
| -$14.81M-74.8% | -$8.47M+33.0% | -$12.65M-59.8% | -$7.91M+66.2% | -$23.4M-261% | ||
| $52K-38.8% | $85K-63.8% | $235K+120% | $107K-20.7% | $135K+800% | ||
| -$52K+38.8% | -$85K+63.8% | -$235K-120% | -$107K+20.7% | -$135K-800% | ||
| $8K— | —— | —— | —— | $6K+4.3% | ||
| $1K-99.9% | $924K+173% | $339K+4,743% | $7K— | $0— | ||
| $329K+1,728% | $18K-74.3% | $70K+268% | $19K-97.3% | $703K+70,200% | ||
| $4.42M+570% | $660K-99.2% | $81.41M— | $0-100% | $20.65M+13,050% | ||
| -$10.44M— | —— | $68.53M+944% | -$8.12M-181% | -$2.89M— | ||
| $1.52M0.0% | $1.52M0.0% | $1.52M-0.1% | $1.53M0.0% | $1.53M-0.4% | ||
| $2.29M-16.8% | $2.75M0.0% | $2.75M0.0% | $2.75M-0.1% | $2.75M+1.9% | ||
| -$10.9M-283% | $5.96M— | $0-100% | $1.35M-57.0% | $3.13M+235% | ||
| -$2.8M-155% | $5.09M— | —— | —— | -$2.78M— | ||
| -$272K0.0% | -$272K+0.4% | -$273K— | —— | -$261K0.0% | ||
| $340K— | —— | —— | -$2.68M-534% | -$423K-132% | ||
| $916K— | —— | —— | —— | $0— | ||
| -$6K-500% | -$1K+90.9% | -$11K-119% | $57K+224% | -$46K-39.4% | ||
| $0— | —— | —— | —— | $5K+300% | ||
| $4.76M— | —— | —— | —— | $21.36M+625% | ||
| $8K— | —— | —— | —— | $6K+4.3% | ||
| $0— | —— | —— | —— | $89K— | ||
| —— | $16.25K0.0% | $16.25K0.0% | $16.25K0.0% | $16.25K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$14.86M-73.7% | -$8.55M+33.6% | -$12.88M-60.6% | -$8.02M+65.9% | -$23.54M-262% | ||
| -$14.86M-73.7% | -$8.55M+33.6% | -$12.88M-60.6% | -$8.02M+65.9% | -$23.54M-262% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aquestive Therapeutics, Inc. generate?
- Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
- Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
